The catastrophic phase of Covid-19 turns the table over with the spread of its disastrous transmission network throughout the world. Covid-19 associated with mucormycosis fungal infection accompanied by opportunistic comorbidities have emerged the myriad of complications and manifestations. We searched the electronic databases of Google Scholar, PubMed, Springer, and Elsevier until June 05, 2021, using keywords. We retrieved the details of confirmed and suspected mucormycosis patients associated with Covid-19. We analyzed the case reports, treatment given for Covid-19, steroids used, associated comorbidities, mucormycosis site involved, and patients survived or dead. Overall, 102 patients of mucormycosis associated with Covid-19 have been reported from India. Mucormycosis was predominant in males (69.6%) rather than females (19.6%), and most of the patients were active Covid-19 cases (70.5%). Steroids were mostly used (68.6%) for the treatment of Covid-19 followed by remdesivir (10.7%). Patients were suffering from diabetes mellitus (88.2%) and severe diabetic ketoacidosis (11.7%). Mucormycosis affects the sino-nasal (72.5%), orbit (24.5%), central nervous system (18.6%), and maxillary necrosis (13.7%) of the patients. The Mortality rate was recorded as 23.5%, and recovery rate was 2.9%. Diabetes mellitus cases are highest in India as compared to other countries, and prevalent use of steroids with the background of Covid-19 becomes an opportunistic environment for mucormycosis fungal infection to survive.

No abstract

No abstract

<b><i>Introduction:</i></b> Migraine is a neurovascular disorder and is clinically characterized by episodic attacks of mild to severe headaches. Due to the involvement of multiple environmental and genetic factors, it has become a much more complex neurological condition to understand. Apart from the environmental variables, a plethora of genes have been implicated, and one such example is <i>ESR</i>1. The present study was focused to find out the association of two important polymorphisms, namely, <i>Pvu</i>II and <i>Xba</i>I of the <i>ESR</i>1 with migraine in the population of Jammu and Kashmir (UT). <b><i>Methods:</i></b> The PCR-RFLP genotyping method was utilized to detect <i>Pvu</i>II and <i>Xba</i>I polymorphism, and the result was confirmed by statistical analysis. <b><i>Results:</i></b> Although we did not find a signification association of <i>ESR</i>-<i>Pvu</i>II polymorphism with migraine susceptibility {OR: 1.14 at 95% CI [0.76–1.71] (<i>p</i> value 0.5)}, a strong association was found with the clinical subtype of migraine; migraine with aura (MA) {OR: 2.014 at 95% CI [1.069–3.792] (<i>p</i> value 0.028)}. Furthermore, a significant association of <i>ESR</i>-<i>Xba</i>I polymorphism was observed with migraine {OR: 1.908 at 95% CI [1.252–2.907] (<i>p</i> value 0.002) and its both clinical subtypes; migraine without aura (MO) {OR: 1.870 at 95% CI [1.186–2.950] (<i>p</i> value 0.006)} and MA {OR: 2.014 at 95% CI [1.069–3.792] (<i>p</i> value 0.028)}. <b><i>Conclusion:</i></b> In conclusion, <i>ESR</i>1-<i>Xba</i>I polymorphism is significantly associated with migraine risk including both subtypes (MA and MO) in the North Indian population of Jammu.